
## Byoung Dae Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6821120/publications.pdf Version: 2024-02-01



RYOLING DAF LEF

#	Article	IF	CITATIONS
1	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	30.7	342
2	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease. Cell, 2014, 157, 472-485.	28.9	239
3	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the United States of America, 2015, 112, 11696-11701.	7.1	207
4	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	14.8	182
5	GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules. Genes and Development, 2011, 25, 1968-1981.	5.9	134
6	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	3.4	131
7	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	2.9	120
8	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, 8.	10.8	87
9	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640.	7.1	70
10	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	8.7	69
11	Pathological Functions of LRRK2 in Parkinson's Disease. Cells, 2020, 9, 2565.	4.1	44
12	Poly (ADP-ribose) in the pathogenesis of Parkinson's disease. BMB Reports, 2014, 47, 424-432.	2.4	40
13	Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage. Cell Death and Disease, 2018, 9, 1125.	6.3	39
14	Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond. BMB Reports, 2015, 48, 243-248.	2.4	36
15	Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017.	1.9	31
16	PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Science Translational Medicine, 2021, 13, .	12.4	30
17	High-Performance Conducting Polymer Nanotube-based Liquid-Ion Gated Field-Effect Transistor Aptasensor for Dopamine Exocytosis. Scientific Reports, 2020, 10, 3772.	3.3	29
18	LRRK2 and membrane trafficking: nexus of Parkinson's disease. BMB Reports, 2019, 52, 533-539.	2.4	23

BYOUNG DAE LEE

#	Article	IF	CITATIONS
19	Inflammatory signals induce the expression of tonicity-responsive enhancer binding protein (TonEBP) in microglia. Journal of Neuroimmunology, 2016, 295-296, 21-29.	2.3	19
20	LRRK2 at the Crossroad of Aging and Parkinson's Disease. Genes, 2021, 12, 505.	2.4	17
21	Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease. International Neurourology Journal, 2014, 18, 171.	1.2	13
22	Decoding the temporal nature of brain GR activity in the NFήB signal transition leading to depressive-like behavior. Molecular Psychiatry, 2021, 26, 5087-5096.	7.9	10
23	Characterization of Parkinson's disease-related pathogenic TMEM230 mutants. Animal Cells and Systems, 2018, 22, 140-147.	2.2	4
24	Improved dynamic monitoring of transcriptional activity during longitudinal analysis in the mouse brain. Biology Open, 2019, 8, .	1.2	2
25	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease. Methods in Molecular Biology, 2012, 795, 45-54.	0.9	2